Why Is OMEROS CORP (OMER) Stock Moving Today?

Why OMER stock is moving today

OMER stock is moving higher today, with shares up approximately 12.4% at the open following news that AstraZeneca's Ultomiris failed in a phase 3 trial for a rare blood disorder. The development reduces competitive pressure for Omeros' Yartemlea in the treatment of thrombotic microangiopathy (TA-TMA), contributing to a positive sentiment for the stock. The market reaction reflects optimism about Omeros' potential market position in this niche therapeutic area.

What Happened

Omeros Corp shares opened at $11.00, a 12.4% increase from the previous close of $9.79. This upward movement was driven by AstraZeneca's announcement that its drug Ultomiris failed in a phase 3 trial for a rare blood disorder. This result is seen as favorable for Omeros, as it removes a key competitor for its drug Yartemlea in the treatment of TA-TMA. The news has led to a reassessment of Omeros' competitive landscape and potential market share in this indication.

What The Data Shows

The stock reached an intraday high of $11.90 at 9:15 AM ET before retreating to a low of $10.50 at 11:45 AM ET. As of the latest data, the stock is trading at $10.89 with a volume of 1.5 million shares, which is 0.9 times the 3-month daily average. Omeros has a market cap of $708.6 million, a P/E ratio of 8.3, and a beta of 2.55. The stock has traded between $3.44 and $17.65 over the past 52 weeks. Recent insider transactions show one sale totaling $87,000, with no insider buys in the last 90 days.

What To Watch

Investors should monitor the company's upcoming earnings report if one is scheduled. Otherwise, tracking the breadth of analyst coverage and any further developments in the competitive landscape for Yartemlea will be important for assessing the stock's trajectory.